QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
a first-in-kind collaboration with Penn State University in the
United States to create a shared research and education facility
for the fast-developing microbiome sciences.
The university-industry partnership will serve
as a beacon for this field by investigating research opportunities
that address challenges and research gaps facing the microbiome,
which involves the research into a community of microorganisms that
can be found living together in any given environment, including
the human body.
In doing so, this new partnership will provide
QIAGEN with a site to support the development of new products as a
testing center. It is also designed to provide vital industry
research and training opportunities for next-generation scientists.
This includes an internship program for graduate students from Penn
State at QIAGEN laboratories at the European operational
headquarters in Hilden, Germany, and helps them prepare for careers
in the biotechnology industry.
“This new partnership with Penn State, one of
the leading academic research institutions in the field of
microbiome research, is anchored by a shared vision for an
interconnection between the health of humans, animals and
ecosystems. It will help shape research, education and outreach in
the young field of the microbiome sciences, and hopefully
accelerate the careers of a new generation of scientists interested
in this field,” said Nitin Sood, Senior Vice President and Head of
the Life Sciences Business Area at QIAGEN. “Additionally, it will
foster relationships with the microbiome research community and
enable us to better develop new products for microbiome research
based on direct customer feedback.”
Seth Bordenstein, Director of the One Health
Microbiome Center, Professor of Biology and Entomology, and Huck
Endowed Chair in the Microbiome Sciences, at Penn State said: “The
‘One Health’ vision shared by QIAGEN and Penn State University is
critical for microbiome research. We are pleased to partner with
the leading provider of microbiome solutions to equip researchers
with the tools to explore how microorganisms flow through humans,
animals, plants and the environment, impacting the health of all
these ecosystems. With this multi-year partnership, we will bridge
the gap between industry and academia and shape the future of
microbiome research.”
Among the various projects in this partnership,
the team will support the worldwide science education program
“Discover the Microbes Within! The Wolbachia Project”. This program
enables students at the middle and high school levels, as well as
those in college, to learn about arthropods (animals without
backbones that have an outer skeleton made of chitin, segmented
bodies and legs with joints, including insects, spiders, mites and
crustaceans) and collect scientific data about the bacterial
endosymbiont (an organism living inside another one for the benefit
of both) Wolbachia pipientis.
This bacterium is estimated to be found in
approximately 50% of the world’s arthropods and has been shown, for
example, to block the reproduction of potentially fatal RNA viruses
such as Dengue, West Nile and Zika virus[1]. Additionally, it is
used to reduce the transmission of these and other viruses spread
by the bite of infected arthropods (arboviruses)[2]. Due to these
real-world impacts, Wolbachia is often used as a model organism to
investigate animal-microbe interactions, genetics, evolution,
ecology and human health.
Microbiome research aims to explore the
relationships between microorganisms such as bacteria, fungi and
viruses, and their hosts. It can help to better understand the
microbiome’s impact on health, diseases and ecological processes in
order to develop novel diagnostic solutions and therapeutic
strategies.
The flagship project at the One Health
Microbiome Center (OHMC) at Penn State’s Huck Institutes of the
Life Sciences will see QIAGEN provide instruments and kits for
preparing and processing microbial samples.
Penn State is among the top 30 public research
universities in the U.S., with more than $1.2 billion in annual
research expenditures. With over 500 members, including 125 faculty
from various Penn State campuses and more than 42 departments, OHMC
is one of the largest organizations of its type in microbiome
research.
QIAGEN’s comprehensive microbiome portfolio
encompasses tools for every aspect of the scientific workflow,
including reliable sample preparation kits optimized for
investigating challenging samples from environmental and human
microbiomes. To ensure reproducibility, QIAGEN offers sample
preparation automation for standardization and reliability. The
extensive range of microbiome solutions also includes downstream
processing technologies such as NGS, digital PCR (dPCR), or
quantitative PCR (qPCR), all complemented by robust bioinformatics
tools for seamless digital analysis.
Learn more about QIAGEN’s solutions for
microbiome research
athttps://www.qiagen.com/us/applications/microbiome.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
About Penn State University
Penn State is a multi-campus, land-grant, public
research University that educates students from around the world,
and supports individuals and communities through integrated
programs of teaching, research and service. Penn State is an R1
university, a classification given by the Carnegie Foundation for
the Advancement of Higher Education to the very best research
universities in America, reaching a record $1.239 billion in
research expenditures during fiscal year 2022-23. The University’s
discovery-oriented, collaborative and interdisciplinary research
and scholarship promote human and economic development, global
understanding, and advancement in professional practice through the
expansion of knowledge and its applications in the natural and
applied sciences, social and behavioral sciences, engineering,
technology, arts and humanities, and myriad professions. The
University’s instructional mission includes undergraduate,
graduate, professional, continuing and extension education, offered
through both resident instruction and distance learning. Penn
State’s educational programs are enriched by the talent, knowledge,
diversity, creativity and teaching and research acumen of its
faculty, students and staff. As Pennsylvania’s sole land-grant
university, Penn State provides unparalleled access to education
and public service to support the citizens of the commonwealth and
beyond. The University engages in collaborative activities with
private sector, educational and governmental partners worldwide to
generate, integrate, apply and disseminate knowledge that is
valuable to society. For more information, visit
www.research.psu.edu.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
[1] Flores, Heater A., and O’Neill, Scott L.: “Controlling
vector-borne diseases by releasing modified mosquitoes” Nature
Reviews Microbiology, 2018.
https://doi.org/10.1038/s41579-018-0025-0 [2] O’Neill, Scott L., et
al. : “Scaled deployment of Wolbachia to protect the community
from dengue and other Aedes transmitted arboviruses” Gates Open
Research, 2018. https://doi.org/10.12688/gatesopenres.12844.1
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024